CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - Scenario, Unspecified [Domain] - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Net product sales	$ 657,819	$ 418,022	$ 1,202,392	$ 780,400
Sanofi collaboration revenue	195,110	142,595	368,466	273,103
Bayer HealthCare collaboration revenue	134,237	97,295	258,083	222,607
Technology licensing and other revenue	11,451	7,788	39,288	15,330
Total revenues	998,617	665,700	1,868,229	1,291,440
Expenses:
Research and development	390,330	294,501	733,443	581,880
Selling, general, and administrative	174,588	96,730	333,579	199,957
Cost of goods sold	60,855	29,945	103,425	57,418
Cost of collaboration and contract manufacturing	27,985	16,434	69,370	32,533
Total expenses	653,758	437,610	1,239,817	871,788
Income from operations	344,859	228,090	628,412	419,652
Other income (expense):
Investment and other income	1,849	1,677	1,930	2,614
Interest expense	(2,748)	(10,177)	(8,917)	(21,790)
Loss on extinguishment of debt	(15,964)	(10,787)	(16,906)	(10,787)
Total other income (expense)	(16,863)	(19,287)	(23,893)	(29,963)
Income before income taxes	327,996	208,803	604,519	389,689
Income tax expense	(133,353)	(112,452)	(333,855)	(225,033)
Net income	$ 194,643	$ 96,351	$ 270,664	$ 164,656
Net income per share - basic	$ 1.89	$ 0.96	$ 2.64	$ 1.65
Net income per share - diluted	$ 1.69	$ 0.85	$ 2.35	$ 1.46
Weighted average shares outstanding - basic	102,886	100,391	102,558	100,085
Weighted average shares outstanding - diluted	115,259	113,032	114,962	113,121
Statements of Comprehensive Income
Net income	$ 194,643	$ 96,351	$ 270,664	$ 164,656
Other comprehensive (loss) income:
Unrealized (loss) gain on marketable securities, net of tax	(28,751)	2,798	(33,098)	5,451
Comprehensive income	$ 165,892	$ 99,149	$ 237,566	$ 170,107